Hercules Capital, Inc.

Hercules Capital reported record second-quarter 2026 results, with revenue rising to US$149.11 million and net income to US$130.18 million, alongside higher earnings per share from continuing operations compared to a year earlier. The company increased its regular quarterly dividend to US$0.47 per share, declared a US$0.07 supplemental distribution, and recently completed a US$321.27 million fixed-income offering of 6.300% senior unsecured notes due 2031. These moves underscore the firm's balance sheet flexibility and shareholder payout capacity following strong investment income. The results highlight the venture lending model's reliance on healthy origination activity and disciplined credit standards, though risks from competition and sector concentration in tech and life sciences remain.

Hercules Capital reported record second-quarter 2026 originations, investment income, and net investment income, alongside higher revenue and net income, with early loan repayments running ahead of guidance. Management highlighted steady portfolio credit quality, strong liquidity, and ongoing contributions from the private credit business. The stock rose 3.01% on the day of the release and 4.39% over the following week, though it remains down 12.94% year to date. The most followed narrative pegs fair value at $19.36 against a last close of $16.42, implying a 15.2% undervaluation, driven by compounding earnings, resilient margins, and a richer future earnings multiple, while noting risks from competition and early prepayments.

TD Cowen initiated coverage of Dyne Therapeutics with a Buy rating on June 26, citing the potential of its Force platform to improve drug delivery in neuromuscular and CNS diseases. The firm highlighted late-stage candidates z-basivarsen for myotonic dystrophy type 1 and z-rostudirsen for exon 51 Duchenne muscular dystrophy mutations as potential top-tier therapies. Separately, Dyne amended its non-dilutive senior secured term loan with Hercules Capital on June 17, receiving $50 million at closing and gaining the option to draw an additional $50 million tranche upon achieving certain milestones, while the final facility was expanded by $25 million to provide up to $125 million in capital at Hercules' discretion.

Lexicon Pharmaceuticals has gained more than 15% over the past month, driven by its inclusion in the Russell 3000 index and strong fiscal first quarter 2026 earnings. The company posted $21.1 million in revenue, far exceeding expectations of $9.78 million, with revenue growing 1,523% year-over-year, boosted by $20 million in development milestones from the Novo Nordisk licensing agreement for the LX9851 obesity program. Liquidity strengthened with a new $100 million loan facility from Hercules Capital, with an initial $55 million funded to support operations for at least the next 12 months. Management highlighted strong progress for the SONATA-HCM Phase 3 trial and plans to resubmit the ZYNQUISTA New Drug Application for type 1 diabetes by mid-2026. Citi raised its price target on the stock to $3.10 from $2.30 and maintained a Buy rating.

4D Molecular Therapeutics has entered into a strategic credit facility agreement with Hercules Capital for up to $200 million. The company drew an initial $20 million at closing, with an additional $30 million available at its option through June 15, 2027, another $100 million upon achieving certain milestones, and the remaining $50 million subject to final lender approval. As of March 31, 2026, 4DMT held $458 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2028. The non-dilutive financing is intended to support the Phase 3 development and pre-commercial planning of its lead gene therapy candidate 4D-150 for wet age-related macular degeneration and diabetic macular edema.

Dyne Therapeutics has amended its senior secured term loan facility with Hercules Capital, increasing total borrowing capacity to up to $400 million. The amendment provides an additional $125 million in potential funding, with $50 million drawn immediately at closing. A new $50 million tranche is available at Dyne's option upon achieving certain milestones, and the final tranche was increased by $25 million to up to $75 million, fundable at Dyne's request and Hercules' discretion. Including the $50 million just funded, Dyne has borrowed $200 million across three tranches and retains access to up to $200 million in future funding. The company plans to use the capital to advance its lead candidates, zeleciment rostudirsen for Duchenne muscular dystrophy and zeleciment basivarsen for myotonic dystrophy type 1, toward potential U.S. launches in the next two years.